145 related articles for article (PubMed ID: 27904955)
1. Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.
Sy SK; Sweeney TD; Ji C; Hoch U; Eldon MA
Cancer Chemother Pharmacol; 2017 Jan; 79(1):57-67. PubMed ID: 27904955
[TBL] [Abstract][Full Text] [Related]
2. Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
Sy SKB; Chia YL; Gordi T; Hoch U; Eldon MA
Cancer Chemother Pharmacol; 2018 May; 81(5):897-909. PubMed ID: 29564497
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
Hoch U; Staschen CM; Johnson RK; Eldon MA
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1125-37. PubMed ID: 25228368
[TBL] [Abstract][Full Text] [Related]
4. [Irinotecan pharmacokinetics].
Chabot GG; Robert J; Lokiec F; Canal P
Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
[TBL] [Abstract][Full Text] [Related]
5. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Awada A; Garcia AA; Chan S; Jerusalem GH; Coleman RE; Huizing MT; Mehdi A; O'Reilly SM; Hamm JT; Barrett-Lee PJ; Cocquyt V; Sideras K; Young DE; Zhao C; Chia YL; Hoch U; Hannah AL; Perez EA;
Lancet Oncol; 2013 Nov; 14(12):1216-25. PubMed ID: 24095299
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.
Lenz HJ; Philip P; Saunders M; Kolevska T; Mukherjee K; Samuel L; Bondarde S; Dobbs T; Tagliaferri M; Hoch U; Hannah AL; Berkowitz M
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1161-1169. PubMed ID: 29043412
[TBL] [Abstract][Full Text] [Related]
7. In vitro cytotoxicity, pharmacokinetics and tissue distribution in rats of MXN-004, a novel conjugate of polyethylene glycol and SN38.
Zhou S; Li N; Wang X; Li C; Tian F; Ren S; Zhang Y; He Y; Qiu Z; Zhao D; Chen X
Xenobiotica; 2014 Jun; 44(6):562-9. PubMed ID: 24308437
[TBL] [Abstract][Full Text] [Related]
8. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
Adkins CE; Nounou MI; Hye T; Mohammad AS; Terrell-Hall T; Mohan NK; Eldon MA; Hoch U; Lockman PR
BMC Cancer; 2015 Oct; 15():685. PubMed ID: 26463521
[TBL] [Abstract][Full Text] [Related]
9. Etirinotecan pegol for the treatment of breast cancer.
López-Miranda E; Cortés J
Expert Opin Pharmacother; 2016; 17(5):727-34. PubMed ID: 26881332
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
Patnaik A; Papadopoulos KP; Tolcher AW; Beeram M; Urien S; Schaaf LJ; Tahiri S; Bekaii-Saab T; Lokiec FM; Rezaï K; Buchbinder A
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1499-506. PubMed ID: 23543270
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
Jameson GS; Hamm JT; Weiss GJ; Alemany C; Anthony S; Basche M; Ramanathan RK; Borad MJ; Tibes R; Cohn A; Hinshaw I; Jotte R; Rosen LS; Hoch U; Eldon MA; Medve R; Schroeder K; White E; Von Hoff DD
Clin Cancer Res; 2013 Jan; 19(1):268-78. PubMed ID: 23136196
[TBL] [Abstract][Full Text] [Related]
12. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
Chester JD; Joel SP; Cheeseman SL; Hall GD; Braun MS; Perry J; Davis T; Button CJ; Seymour MT
J Clin Oncol; 2003 Mar; 21(6):1125-32. PubMed ID: 12637480
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Schaaf LJ; Hammond LA; Tipping SJ; Goldberg RM; Goel R; Kuhn JG; Miller LL; Compton LD; Cisar LA; Elfring GL; Gruia G; McGovren JP; Pirotta N; Yin D; Sharma A; Duncan BA; Rothenberg ML
Clin Cancer Res; 2006 Jun; 12(12):3782-91. PubMed ID: 16778106
[TBL] [Abstract][Full Text] [Related]
15. Preparation, Pharmacokinetic Profile, and Tissue Distribution Studies of a Liposome-Based Formulation of SN-38 Using an UPLC-MS/MS Method.
Li K; Wang S
AAPS PharmSciTech; 2016 Dec; 17(6):1450-1456. PubMed ID: 26831446
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
[TBL] [Abstract][Full Text] [Related]
17. Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer.
Bardhi E; Marchetti C; Scopelliti A; Musacchio L; Tomao F; Schiavi M; Carraro C; Palaia I; Monti M; Muzii L; Benedetti Panici P
Expert Opin Investig Drugs; 2019 Aug; 28(8):667-673. PubMed ID: 31353973
[No Abstract] [Full Text] [Related]
18. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
Zhao H; Rubio B; Sapra P; Wu D; Reddy P; Sai P; Martinez A; Gao Y; Lozanguiez Y; Longley C; Greenberger LM; Horak ID
Bioconjug Chem; 2008 Apr; 19(4):849-59. PubMed ID: 18370417
[TBL] [Abstract][Full Text] [Related]
19. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
20. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.
Meyer-Losic F; Nicolazzi C; Quinonero J; Ribes F; Michel M; Dubois V; de Coupade C; Boukaissi M; Chéné AS; Tranchant I; Arranz V; Zoubaa I; Fruchart JS; Ravel D; Kearsey J
Clin Cancer Res; 2008 Apr; 14(7):2145-53. PubMed ID: 18381956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
